Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURMOUNT-OSA: Tirzepatide Once Weekly in Obstructive Sleep Apnea with Obesity
2021-004551-16Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obstructive sleep apnea hypopnea syndrome (OSAHS) and obesity comparing Tirzepatide with Placebo (2 arms). Primary endpoint: Percent change in AHI from baseline to week 52. Started May 2022; status: completed.
02
Drugs
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)obesity
Beyond the preview
Go deeper on 2021-004551-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004551-16.